Semax Administration Routes in Research: What Studies Used

Semax is a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10), extended at the C-terminus with a Pro-Gly-Pro tripeptide that was intended to slow enzymatic breakdown. Because it is a short, water-soluble peptide rather than a small lipophilic molecule, the way it is delivered in an experiment shapes what an experiment can measure. This guide summarises the delivery categories that appear in the published literature, why investigators have described choosing them, and what the verified papers below actually reported. It is a description of laboratory and clinical study methods, not a procedure for anyone to follow.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance mentioned here. Nothing below describes how to prepare, obtain or use Semax, and none of the cited papers were designed to validate any preparation made outside a research or pharmaceutical setting.

Why route matters for a peptide like Semax

Peptides of this size face three practical obstacles that shape experimental design. First, gastrointestinal and plasma peptidases cleave peptide bonds rapidly, so material given by mouth may never reach circulation intact. Second, hydrophilic peptides cross membranes poorly, which limits passive absorption across the gut wall and the blood–brain barrier. Third, hepatic first-pass metabolism removes much of whatever is absorbed enterally. These are general pharmacology constraints rather than findings from any single Semax paper, and they explain why the Semax literature is dominated by routes that bypass the gut: intranasal instillation and parenteral administration in animals, or direct application to tissue and cells in vitro.

A fourth consideration is specific to central-nervous-system research. Investigators working with neuropeptides frequently justify intranasal delivery on the grounds that the olfactory and trigeminal pathways offer a route from the nasal mucosa toward the brain that does not require the molecule to survive the gut or first-pass metabolism. Whether a given study demonstrated that pathway, or simply used it as a rationale, is a question that has to be answered from each paper's own methods and pharmacokinetic data — and most of the verified papers summarised here were outcome studies rather than pharmacokinetic ones.

Delivery categories that appear in the Semax literature

Intranasal solutions

Semax is registered as a medicine in Russia in the form of a nasal solution, and it has no marketing approval from the US Food and Drug Administration; in the United States material sold under the name is research-use-only and is not an approved drug for any indication. That regulatory background matters when reading the clinical literature, because human work on Semax has come out of the setting where the intranasal product exists. A Russian clinical report examined the peptide in patients at different stages of ischaemic stroke and reported on efficacy across those stages (PMID 29798983). Readers evaluating that literature should note that single-centre reports published in national journals are not equivalent to large multi-centre randomised trials, and that the abstract-level record does not substitute for full methods.

Human neuroimaging work has also been performed with intranasally administered peptides of this family. A functional connectomic study examined the effects of Selank and Semax on brain network measures, and researchers used that approach to look for distributed changes in connectivity rather than a single regional signal (PMID 32342318). Connectomic designs are attractive precisely because a nasal solution produces a systemic exposure that cannot be localised in advance, so a whole-brain readout is more informative than a single pre-specified region of interest.

Parenteral administration in animal models

In rodent work, systemic administration by intraperitoneal, subcutaneous or intramuscular routes is common because it delivers a known quantity of peptide reproducibly, avoids uncertainty about how much solution stayed in a small animal's nasal cavity, and allows precise timing relative to an injury or a behavioural test. Several of the verified papers used systemic administration in whole animals; the specific route and schedule for each is stated in the full methods of the original article rather than in the abstract, so this guide does not assign numbers to individual studies.

A 2025 study in female mice with spinal cord injury reported that Semax acted on the μ-opioid receptor gene Oprm1, promoting deubiquitination and functional recovery in that model (PMID 40692165). Studies of this kind depend on systemic delivery beginning at a defined interval after a surgically produced lesion, which is one reason investigators choose an injectable route over nasal instillation in anaesthetised or impaired animals.

In cerebral ischaemia models, researchers reported that Semax and the Pro-Gly-Pro fragment activated transcription of neurotrophins and their receptor genes after ischaemia (PMID 19633950), and a later molecular-biology report described suppression of mRNA transcripts encoding proinflammatory mediators induced by reversible brain ischaemia in rats (PMID 34097675). Transcriptomic endpoints require tissue collection at fixed times after administration, so a route with predictable absorption kinetics simplifies interpretation.

Behavioural and neurochemical models follow the same logic. One study administered Semax in a 6-OHDA rat model of Parkinson-like pathology and reported effects on the animals' behaviour (PMID 28702721). Another reported that Semax attenuated behavioural and neurochemical alterations in white rats following early-life fluvoxamine exposure (PMID 33418449). A 2025 review-style report in an Alzheimer's disease animal model discussed the potential of Semax and a derivative for correcting pathological impairments in that model (PMID 41479572). In each case the endpoints were measured in the living animal or in tissue harvested afterwards, which constrains the practical choices available for delivery.

Oral administration

Oral dosing is the least represented category in the Semax literature, and none of the verified papers summarised here reported an oral bioavailability figure. The general expectation for a seven-residue peptide is extensive gastrointestinal degradation, and the presence of the Pro-Gly-Pro extension was intended to improve stability rather than to confer enteral absorption. Claims that Semax is orally active are not supported by anything in this verified set, and the absence of data should not be read as evidence either way.

In vitro and ex vivo application — not a "route"

A substantial part of the mechanistic literature never involves a whole organism. A 2025 report examined the effect of Semax on intracellular calcium dynamics in rat brain neurons, where the peptide was applied directly to the neuronal preparation and calcium signals were recorded (PMID 41171324). Chemistry-level work has also been published without any administration at all: one study examined how N-terminal acetylation of Semax influenced copper(II) and zinc(II) coordination and associated biological properties (PMID 27586814). That paper is relevant to formulation questions because chemical modification and metal binding can change a peptide's stability and behaviour in solution — but it says nothing about what happens after any route of administration in a person.

Finally, some of the frequently cited Semax literature is not experimental at all. A 2007 Medical Hypotheses article proposed Semax as a potential agent for attention-deficit hyperactivity disorder and Rett syndrome (PMID 16996699). Hypothesis papers contain no administration data and no outcome data, and they are often mistaken online for trial evidence.

Study types and what was reported

What searches about "making a nasal spray" run into

One of the most common queries that reaches pages like this one asks how a Semax nasal spray is made. The honest answer from the literature side is that peer-reviewed papers describe pharmaceutical or laboratory preparation of a defined solution under controlled conditions, with characterised material, verified concentration, controlled pH and sterility testing — and that none of the verified papers here provide, validate or endorse any preparation method for use outside those settings. PeptideU does not publish preparation procedures.

There is also a regulatory layer. Sterile compounding in the United States is governed by pharmacy law and by United States Pharmacopeia standards for sterile and hazardous preparations, and it is performed by licensed facilities. Material labelled "research use only" is, by that label, not intended for human use, and RUO labelling carries no assurance of identity, purity, endotoxin content or sterility. These are regulatory facts rather than legal advice; anyone with a specific legal question should consult a qualified attorney, and anyone with a health question should consult a licensed physician.

Bioavailability by route: what the verified set does and does not establish

A reader looking for a table of absolute bioavailability percentages by route will not find one in this set of papers. The verified literature summarised above is overwhelmingly composed of outcome studies — gene transcription, inflammatory mediator mRNA, behaviour, calcium signalling, clinical scales — rather than pharmacokinetic studies with plasma or brain concentration–time curves. That means the following statements are supportable from this set, and little more:

• Biological effects have been reported in whole animals after systemic administration in ischaemia, spinal cord injury, parkinsonism, early-life drug exposure and Alzheimer's-model designs (PMID 19633950, PMID 40692165, PMID 41479572).
• Effects have also been reported when the peptide was applied directly to neurons, which removes absorption and distribution from the question entirely (PMID 41171324).
• Human data in this set come from a stroke report and a connectomic analysis, not from dose-ranging or comparative-route trials (PMID 29798983, PMID 32342318).
• No paper in this set reported oral bioavailability, and no paper compared nasal against subcutaneous or intramuscular exposure head to head.

Because of that, cross-route comparisons circulating in popular summaries are generally extrapolations from other peptides or from unpublished sources, not from the studies cited here.

Adverse Events and Tolerability: What Studies Report

The verified abstracts summarised on this page were mostly designed around efficacy or mechanism endpoints rather than systematic safety monitoring, so they are a weak basis for any tolerability conclusion. The closest organ-level observation in this set is a 2017 report on the morphofunctional state of hepatocytes under chronic emotional and painful stress, in which researchers examined liver cell morphology in the context of Semax administration (PMID 28577097). Behavioural and neurochemical studies such as the early-life fluvoxamine exposure model recorded changes in animal behaviour as their primary outcome rather than as adverse-event surveillance (PMID 33418449). Absence of reported adverse events in an abstract is not the same as demonstrated safety, and non-sterile or uncharacterised material introduces hazards — contamination, incorrect concentration, endotoxin — that no published efficacy study addresses.

Limits of this evidence base

Most Semax research has been conducted in rodents, much of it in models of acute injury; species differences in peptidase activity and nasal anatomy make rodent-to-human extrapolation uncertain. Several papers are short-format reports in Russian-language journals, where abstract-level detail is limited. Sample sizes, blinding and randomisation are not visible from abstracts, and one influential citation is a hypothesis article with no data at all (PMID 16996699). Anyone assessing route-related claims should read the full methods sections of the original papers rather than relying on secondary summaries, including this one.

References

• Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain (Molekuliarnaia Biologiia, 2021)
• The efficacy of semax in the treatment of patients at different stages of ischemic stroke (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018)
• Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome (Medical Hypotheses, 2007)
• Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties (Journal of Inorganic Biochemistry, 2016)
• The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons (Bulletin of Experimental Biology and Medicine, 2025)